Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 28, 2026 · Filed Oct 30, 2026
A major shareholder of Lycia Therapeutics paid $115K out of pocket for Lycia Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$115,047
Shares × reported transaction price
$100K–$500K
+0.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 6 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +11.7% | +0.1% | +11.6% |
Past results only. Not a forecast.
Insider buying
Traded Nov 2 · filed 2 days later
A major shareholder of Lycia Therapeutics paid $224K out of pocket for Lycia Therapeutics shares.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Insider buying
Traded Oct 29 · filed 1 day later
A major shareholder of Lycia Therapeutics paid $26K out of pocket for Lycia Therapeutics shares.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.